Efficacy of Dienogest for Prevention of Endometriosis Recurrence: A Systematic Review and Meta-Analysis

Hussain MA Assiri, Mashail AS Alomari, Atheer DM Alshehri, Asma SY Alahmari, Manal M Alasmari
In: World Family Medicine Journal /Middle East Journal of Family Medicine · 2022 · vol. 20(11) · doi:10.5742/mewfm.2022.95251391 · W4307756746
review OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Postoperative dienogest treatment significantly reduces endometriosis recurrence rates, improves pain, and lowers side effects compared to control groups.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper is a systematic review and meta-analysis evaluating the efficacy of dienogest for preventing endometriosis recurrence, synthesizing evidence from published studies. The authors pooled outcomes across included trials to estimate dienogest’s effect on recurrence prevention. A key limitation is that, as with many systematic reviews, the reliability of the pooled estimate depends on the quality, design heterogeneity, and completeness of the underlying studies. This paper is centrally about endometriosis — specifically, dienogest’s efficacy for preventing endometriosis recurrence.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Aim of Study: To evaluate the efficacy of postoperative dienogest for prevention of endometriosis recurrence. Methods: Several databases were used to search for recent studies (i.e., published in 2016-2020). The search keywords included: “dienogest,” and “endometr*,” Patients who were not treated with dienogest were considered controls. Reviews, comments, animal trials, case reports, abstracts, single-arm studies, low-quality studies, and non-English articles were excluded. The primary outcome of interest was to determine the odds of recurrence in patients who received dienogest compared to controls who were managed expectantly, or offered a substitute hormonal therapy. Secondary outcomes included pain improvement and side effects of received treatment. Results: Included studies comprised three retrospective cohort studies, and two prospective cohort studies. These studies included 608 patients; 216 were managed in the Dienogest Group, while 392 were managed in the Control Group (163 received hormonal suppression, and 228 received no treatment). Overall, the recurrence rate of endometriosis in patients receiving Dienogest was 8/216, i.e., 3.7 events per 100 treated women over a mean duration of 28.5 months, and 1.3 recurrences per 1000 woman-months. On the other hand, the recurrence rate of endometriosis in the Control Group was 69/392 recurrences over a mean duration of 29.3 months, i.e., 17.6 per 100 women (6.0 recurrences per 1000 women-months). Difference in recurrence rates between study groups was statisticallysignificant (X2=24.3, p<0.001). Reported recurrence rates were significantly less among patients in the Dienogest Group than those in the Control Group, with a pooled estimate of RR = 0.239, and 95% CI: 0.119-0.488. Generally, patients in the Dienogest Group experienced less pain and less side effects than those in the control group. Conclusions: Endometriosis patients who receive dienogest following conservative surgery have a significantly lower rate of recurrence, better pain control, and less side effects than their control counterparts. Key Words: Endometriosis, Dienogest, Goserelin, Systematic Review, Meta-Analysis,

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK